Kala Pharmaceuticals, Inc. (KALA)
KALA Stock Price Chart
Explore Kala Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze KALA price movements and trends.
KALA Company Profile
Discover essential business fundamentals and corporate details for Kala Pharmaceuticals, Inc. (KALA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
20 Jul 2017
Employees
38.00
Website
https://www.kalarx.comCEO
Todd Bazemore
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
KALA Financial Timeline
Browse a chronological timeline of Kala Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$1.22.
Earnings released on 8 Aug 2025
EPS came in at -$1.71 surpassing the estimated -$1.82 by +6.04%.
Earnings released on 14 May 2025
EPS came in at -$1.41 surpassing the estimated -$2.03 by +30.54%.
Earnings released on 31 Mar 2025
EPS came in at -$1.74 surpassing the estimated -$2.28 by +23.68%, while revenue for the quarter reached $254.00K .
Earnings released on 12 Nov 2024
EPS came in at -$1.93 surpassing the estimated -$2.43 by +20.58%.
Earnings released on 6 Aug 2024
EPS came in at -$3.16 surpassing the estimated -$4.41 by +28.34%.
Earnings released on 14 May 2024
EPS came in at -$4.20 falling short of the estimated -$2.89 by -45.33%.
Earnings released on 29 Mar 2024
EPS came in at -$3.18 surpassing the estimated -$3.62 by +12.15%, while revenue for the quarter reached $70.00K .
Earnings released on 13 Nov 2023
EPS came in at -$3.41 falling short of the estimated -$2.15 by -58.60%.
Earnings released on 4 Aug 2023
EPS came in at -$4.36 falling short of the estimated -$3.19 by -36.68%.
Earnings released on 9 May 2023
EPS came in at -$6.99 falling short of the estimated -$5.10 by -37.06%.
Earnings released on 3 Mar 2023
EPS came in at -$7.97 falling short of the estimated -$6.56 by -21.49%, while revenue for the quarter reached $1.23M .
Earnings released on 8 Nov 2022
EPS came in at $19.25 surpassing the estimated $10.75 by +79.07%, while revenue for the quarter reached $420.00K , missing expectations by -99.33%.
Stock split effective on 21 Oct 2022
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 26 Aug 2022
Shares were split 2 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Aug 2022
EPS came in at -$19.00 surpassing the estimated -$22.00 by +13.64%, while revenue for the quarter reached $2.10M , beating expectations by +4.05%.
Earnings released on 16 May 2022
EPS came in at -$22.50 falling short of the estimated -$18.00 by -25.00%, while revenue for the quarter reached $1.37M , missing expectations by -55.82%.
Earnings released on 29 Mar 2022
EPS came in at -$34.00 falling short of the estimated -$21.50 by -58.14%, while revenue for the quarter reached $1.86M , missing expectations by -45.07%.
Earnings released on 15 Nov 2021
EPS came in at -$21.50 surpassing the estimated -$22.50 by +4.44%, while revenue for the quarter reached $3.07M , missing expectations by -42.24%.
Earnings released on 5 Aug 2021
EPS came in at -$28.50 falling short of the estimated -$22.00 by -29.55%, while revenue for the quarter reached $3.05M , missing expectations by -41.89%.
Earnings released on 5 May 2021
EPS came in at -$24.50 surpassing the estimated -$25.50 by +3.92%, while revenue for the quarter reached $3.27M , missing expectations by -21.84%.
Earnings released on 25 Feb 2021
EPS came in at -$27.50 falling short of the estimated -$23.00 by -19.57%, while revenue for the quarter reached $2.24M , beating expectations by +24.32%.
Earnings released on 5 Nov 2020
EPS came in at -$25.00 falling short of the estimated -$22.00 by -13.64%, while revenue for the quarter reached $2.22M , beating expectations by +13.64%.
KALA Stock Performance
Access detailed KALA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.